Wang S, Zhu Y, Chen T, Lin C, Chen L, Niu Y, Li C. Is COVID-19 Vaccination Beneficial for Tumor Patients: A Cross-Sectional Investigation in China.
Immun Inflamm Dis 2024;
12:e70069. [PMID:
39601455 PMCID:
PMC11600451 DOI:
10.1002/iid3.70069]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2024] [Revised: 10/12/2024] [Accepted: 10/30/2024] [Indexed: 11/29/2024] Open
Abstract
INTRODUCTION
Tumor patients take a high risk of SARS-CoV-2 infection, high incidence of serious events, poor prognosis and high mortality in the coronavirus disease 2019 (COVID-19) epidemic, but there is still lack of supporting evidence that the COVID-19 vaccination is beneficial for tumor patients to encourage them to receive the vaccination.
METHODS
A cross-sectional study was conducted in Shantou, China and questionnaires were collected in the hospitals from February 13, 2023 to April 23, 2023. Using the receiving of COVID-19 vaccination as the primary outcome, descriptive, univariate and multivariate analyses were generated.
RESULTS
161 out of 241 patients (66.80%) had received at least one dose of COVID-19 vaccine and 61.00% patients had been infected with SARS-CoV-2. Patients with general symptoms (p = 0.013) and others (p = 0.022) had a higher proportion of nonvaccinated patients than vaccinated ones. In the multivariate analysis, age (aOR = 0.971, 95% CI = 0.946-0.997, p = 0.031), the cognition of vaccines' impact on tumor treatment (aOR = 4.475, 95% CI = 1.772-11.299, p = 0.002), time since tumor diagnosis (aOR = 4.586, 95% CI = 2.122-9.909, p < 0.001) were identified as factors of COVID-19 vaccination uptake.
CONCLUSION
COVID-19 vaccination in China offers numerous advantages for tumor patients, helping to alleviate symptoms following infection and potentially decreasing the chances of tumor metastasis and recurrence.
Collapse